IL191271A0 - Adenosine a3 receptor agonists for the treatment of dry eye disorders - Google Patents

Adenosine a3 receptor agonists for the treatment of dry eye disorders

Info

Publication number
IL191271A0
IL191271A0 IL191271A IL19127108A IL191271A0 IL 191271 A0 IL191271 A0 IL 191271A0 IL 191271 A IL191271 A IL 191271A IL 19127108 A IL19127108 A IL 19127108A IL 191271 A0 IL191271 A0 IL 191271A0
Authority
IL
Israel
Prior art keywords
adenosine
treatment
receptor agonists
dry eye
eye disorders
Prior art date
Application number
IL191271A
Other versions
IL191271A (en
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Priority to IL191271A priority Critical patent/IL191271A/en
Publication of IL191271A0 publication Critical patent/IL191271A0/en
Publication of IL191271A publication Critical patent/IL191271A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
IL191271A 2006-01-27 2008-05-06 Pharmaceutical compositions for treating a condition of dry eye comprising an a3 adenosine receptor agonist IL191271A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL191271A IL191271A (en) 2006-01-27 2008-05-06 Pharmaceutical compositions for treating a condition of dry eye comprising an a3 adenosine receptor agonist

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76250606P 2006-01-27 2006-01-27
PCT/IL2006/000130 WO2007086044A1 (en) 2006-01-27 2006-02-01 Adenosine a3 receptor agonists for the treatment of dry eye disorders
IL191271A IL191271A (en) 2006-01-27 2008-05-06 Pharmaceutical compositions for treating a condition of dry eye comprising an a3 adenosine receptor agonist

Publications (2)

Publication Number Publication Date
IL191271A0 true IL191271A0 (en) 2009-08-03
IL191271A IL191271A (en) 2014-03-31

Family

ID=36794417

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191271A IL191271A (en) 2006-01-27 2008-05-06 Pharmaceutical compositions for treating a condition of dry eye comprising an a3 adenosine receptor agonist

Country Status (9)

Country Link
EP (1) EP1976494A1 (en)
JP (2) JP5185139B2 (en)
KR (1) KR101037095B1 (en)
CN (1) CN101365430B (en)
AU (1) AU2006336834B2 (en)
BR (1) BRPI0621052A2 (en)
CA (1) CA2622975C (en)
IL (1) IL191271A (en)
WO (1) WO2007086044A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646685B (en) 2007-03-14 2014-12-17 坎-菲特生物药物有限公司 Process for the synthesis of ib-meca
IL184620A0 (en) * 2007-07-15 2008-01-20 Can Fite Biopharma Ltd Composition for the treatment of inflammation
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8796291B2 (en) 2008-08-01 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
JP5849044B2 (en) * 2009-05-17 2016-01-27 キャン−ファイト バイオファーマ リミテッド A3 adenosine receptor agonists for reducing intraocular pressure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
JPH10158188A (en) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd Composition for treating cornea
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US20060100167A1 (en) * 2002-09-27 2006-05-11 Wood Christopher B Methods and compositions for the treatment of autoimmune disorders using clofarabine
WO2005121320A1 (en) * 2004-06-10 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. Autonomouos replication promoter for stem cells
ES2432113T3 (en) * 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Adenosine A3 receptor agonists for the treatment of dry eye disorders, including Sjogren's syndrome

Also Published As

Publication number Publication date
KR20080090517A (en) 2008-10-08
WO2007086044A1 (en) 2007-08-02
AU2006336834B2 (en) 2009-12-10
KR101037095B1 (en) 2011-05-26
CN101365430A (en) 2009-02-11
CA2622975A1 (en) 2007-08-02
EP1976494A1 (en) 2008-10-08
JP2013032396A (en) 2013-02-14
JP2009524647A (en) 2009-07-02
CN101365430B (en) 2011-09-21
AU2006336834A1 (en) 2007-08-02
JP5185139B2 (en) 2013-04-17
IL191271A (en) 2014-03-31
BRPI0621052A2 (en) 2012-07-17
CA2622975C (en) 2011-05-03

Similar Documents

Publication Publication Date Title
HUS1900005I1 (en) Improved nanobodies tm for the treatment of aggregation-mediated disorders
EP2101785A4 (en) Treatment for dry eye
PL1778239T3 (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
WO2009137843A9 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
IL192690A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
PL1993577T3 (en) Use of non-digestable sacharides for giving an infant the best start after birth
EP1981526A4 (en) Adiponectin for treatment of various disorders
GB0612096D0 (en) Functional imaging of the retina
IL199017A0 (en) Trkb agonists for treating autoimmune disorders
IL195560A0 (en) Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
SI2197883T1 (en) Catecholamine derivative useful for the treatment of parkinson's disease
IL191271A0 (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders
EP2139475A4 (en) The use of pde7 inhibitors for the treatment of movement disorders
ZA200901523B (en) Use of extracts for the treatment of viral disorders
EP2318010A4 (en) Treating various disorders using trkb agonists
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
HK1098155A1 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
ZA200904281B (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
IL197695A0 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
PL2129373T3 (en) Use of genistein for treating dry eye syndrome
IL205535A0 (en) S- alkylisothiouronium derivatives for treating uterine hypercontractility disorders
GB0604782D0 (en) Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders
IL193414A0 (en) Meridamycin analogues for the treatment ofneurodegenererative disorders
HK1129112A1 (en) 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees